Page 2 - Nasdaq Impl News Today

Cost-Saving Measures Eliminate Pipeline Programs and Reduce Headcount by 16 PercentCompany will Continue to Drive Trudhesa Growth Via 90 Field-Based Sales...

SEATTLE, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative...

Impel NeuroPharma (NASDAQ:IMPL – Get Rating) is one of 937 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its peers? We will compare Impel NeuroPharma to similar companies based on the strength of its valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk. Analyst Ratings This is […]

Impel NeuroPharma (NASDAQ:IMPL – Get Rating) is one of 937 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its rivals? We will compare Impel NeuroPharma to similar companies based on the strength of its valuation, risk, analyst recommendations, dividends, profitability, earnings and institutional ownership. Profitability This table compares Impel NeuroPharma […]

Impel NeuroPharma (NASDAQ:IMPL – Get Rating) released its quarterly earnings results on Thursday. The company reported ($1.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.21), MarketWatch Earnings reports. IMPL stock opened at $7.52 on Friday. Impel NeuroPharma has a twelve month low of $5.72 and a twelve month high […]

Impel NeuroPharma, Inc. (NASDAQ:IMPL – Get Rating) was the recipient of a significant growth in short interest in February. As of February 28th, there was short interest totalling 408,100 shares, a growth of 26.0% from the February 13th total of 323,900 shares. Based on an average trading volume of 133,100 shares, the days-to-cover ratio is […]

Data Will Evaluate Exploratory Efficacy Data from STOP-301 Study Evaluating INP104 Consistency of Response, Recurrence and Sustained Response Findings...